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Abstract Cannabis and heavy alcohol use potentially
increase HIV transmission by increasing risky drug
behaviors. We studied 404 subjects entering treatment for
heroin dependence, in St. Petersburg, Russia. We used the
HIV Risk Assessment Battery (RAB) drug subscale to
measure risky drug behavior. Although all heavy alcohol
users had risky drug behaviors, their drug RAB scores did
not differ from non-heavy alcohol users in unadjusted or
adjusted analyses. Cannabis use was signiﬁcantly associ-
ated with drug RAB scores in unadjusted analyses (mean
difference 1.7 points) and analyses adjusted for age, sex,
and employment (mean difference 1.3 points). When also
adjusting for stimulant use, the impact of cannabis use was
attenuated and no longer statistically signiﬁcant (mean
difference 1.1 points). Because of the central role of risky
drug behaviors in the Russian HIV epidemic, it is important
to understand how the use of multiple substances, including
cannabis and alcohol, impacts risky drug behaviors.
Keywords Cannabis  Alcohol  Russia  HIV 
Risk behaviors
Introduction
Since the mid-1990s, HIV infection in the Russian Federa-
tion has become the largest HIV epidemic in Europe with an
estimated 860,000 (range: 420,000–1.4 million) people liv-
ing with HIV in 2003 (UNAIDS, 2005). Injection drug use
hasdriventhisrapidgrowthwithmorethan80%ofofﬁcially
reported HIV cases occurring among injection drug users
(IDUs) (Dehne, Khodakevich, Hamers, & Schwartlander,
1999; Dehne, Pokrovskiy, Kobyshcha, & Schwartlander,
2000).PreventingHIVtransmissioninRussiaischallenging
because unsafe injection practices, such as sharing needles,
arecommon(Shaboltaset al.,2006),andopioidreplacement
therapy with methadone or buprenorphine is illegal. Nal-
trexone is approved and was shown to prevent relapse to
heroin use over a 6-month period in 42–44% of subjects, but
ithasnotbeenwidelyusedsinceitscost($3.50/50 mgtablet)
is prohibitive (Krupitsky et al., 2004b; Krupitsky et al.,
2006).WithHIVinfectionratesamongIDUsashighas30%
(Kozlov et al., 2006; Krupitsky et al., 2004a; Shaboltas
et al., 2006), the epidemic is crossing over into other risk
groups, such as sex workers and sexual partners of injectors
(UNAIDS, 2005).
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alcohol consumption. Nationally representative samples
from 1992 to 2004 report about 70% of men and 45% of
women drink alcohol (Zohoori, Banchette, & Popkin,
2005). Binge drinking is particularly popular in Russia,
where the 20% of men with the greatest intake average
more than 100 g (i.e., seven drinks) of alcohol per day
(McKee, 1999). With an estimated one third of all deaths in
Russia in 1994 related to alcohol, alcohol use is a signiﬁ-
cant Russian public health issue (Nemtsov, 2002; World
Health Organization, 2004). Emerging evidence shows
active alcohol use among HIV-infected patients in Russia
and associations between heavy drinking and HIV risk
behaviors (Benotsch et al., 2006; Krupitsky et al., 2005;
Somlai et al., 2002).
Little has been published on the potential association
between cannabis use and HIV risk behaviors, yet it is the
most abused illicit drug in Russia (United Nations Ofﬁce
on Drugs and Crime, 2006). Among 15 and 16 year olds,
5% are monthly users, 22% are lifetime users and 24%
report cannabis is easily available (Hibell et al., 2004). Use
of other drugs, such as stimulants, has been linked to HIV
transmission and risk behaviors in several populations
(Buchanan et al., 2006; Lorvick, Martinez, Gee, & Kral,
2006; Molitor et al., 1999; Pechansky et al., 2006). A
recent study among HIV-negative IDUs in St. Petersburg,
Russia reports increased HIV seroconversion among IDUs
who inject stimulants (Kozlov et al., 2006).
With a rapidly expanding HIV epidemic among IDUs, in
the setting of high levels of cannabis and alcohol con-
sumption, it is important to determine whether cannabis
and alcohol use impacts risky drug behaviors. If HIV
transmission is increased by cannabis or alcohol con-
sumption, efforts to reduce cannabis or alcohol use may be
effective HIV prevention strategies. We examined the
association of cannabis use and alcohol use with HIV drug-
risk behaviors in Russian drug users in this secondary
analysis of baseline data from three randomized control
trials conducted between 1999 and 2005.
Methods
Participants
We studied 404 patients undergoing treatment for heroin
dependence in and around St. Petersburg. Between 1999
and 2002, 332 of these subjects were recruited into two
randomized controlled trials of naltrexone for relapse pre-
vention (Krupitsky et al., 2004b; Krupitsky et al., 2006).
Trained physician research associates recruited these sub-
jects during inpatient treatment at addiction hospitals
afﬁliated with the St. Petersburg Pavlov State Medical
University or by referral from community psychiatrists
after outpatient detoxiﬁcation. Eligibility criteria for these
two trials were identical: a diagnosis of heroin dependence;
age between 18 and 40 years; education at the high school
level or above; at least one relative willing to support the
subject’s treatment and supervise adherence to study
medications; a stable address with a working phone; no
regular use of psychiatric medication; a negative pregnancy
test and commitment to contraceptive use, if female; and
abstinence from heroin and other substances for at least one
week prior to study entry.
The remaining 72 subjects were the heroin dependent
subgroup of the Russian PREVENT (Partnership to Reduce
the Epidemic Via Engagement in Narcology Treatment)
study. PREVENT was a randomized controlled trial of an
HIV prevention intervention with the goal of reducing HIV
sexual risk behaviors (Samet et al., 2006). PREVENT
subjects were enrolled in 2004 and 2005. Trained physician
research associates approached patients at the Leningrad
Regional Center for Addictions and the Medical Narcology
Rehabilitation Center after initial detoxiﬁcation, and as-
sessed eligibility, offered participation, and conducted
assessments. Eligibility criteria included age 18 years and
older; no alcohol or other abused substances for at least
48 h; reported unprotected anal or vaginal sex in the past
6 months; willingness to undergo HIV testing per standard
narcology hospital protocols or previous diagnosis of HIV
infection; and provision of reliable contact information
(i.e., a home telephone number, an address within 150 km
of St. Petersburg, and a friend or family contact).
In the current analysis, we combined these cohorts, as
subjects were recruited from the same geographic area,
under similar conditions, and with similar entry criteria and
were assessed with similar baseline study instruments and
methods. All subjects provided written informed consent
prior to enrollment in the studies.
Measures
Baseline assessment in each cohort included the following:
demographic survey; the Risk Assessment Battery (RAB)
to assess HIV drug risk behavior in the past 6 months
(Metzger et al., 1992; Metzger, Navaline, & Woody, 2001;
Navaline et al., 1994); and the 30-day Timeline Follow-
back (TLFB) survey for alcohol and cannabis use (Fals-
Stewart, O’Farrell, Freitas, McFarlin, & Rutigliano, 2000;
Sobell & Sobell, 1992; Sobell & Sobell, 1995). For the
Naltrexone cohort, stimulant use was assessed using the
30-day TLFB. We categorized subjects with any stimulant
use in the 30 days prior as stimulant users. For the PRE-
VENT cohort, stimulant use in the last 30 days was
assessed using the Addiction Severity Index (ASI)
(McLellan et al., 1985). The ASI includes questions about
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123cocaine and amphetamine use in the past 30 days. Those
subjects who answered yes to either of these questions
were categorized as stimulant users. All study instruments
were translated into Russian and checked for clarity by
Russian research staff. Trained research staff delivered all
survey instruments in one-on-one conﬁdential sessions,
except in the Russian PREVENT cohort, where the RAB
was administered by an Audio Computer-Assisted Self-
Interviewing (ACASI) System. ACASI allows additional
privacy, minimizes literacy issues, encourages truth telling,
and provides an identical recording of each question. Using
this system has been shown to enhance the quality of self-
report behavioral assessments and to provide an acceptable
method for collecting self-reports of HIV risk behavior
(Newman et al., 2002). HIV infection was recorded as part
of the intake assessment for the PREVENT cohort, but not
for the naltrexone cohorts. Subjects in all cohorts were
compensated US$ 5 for participation in the baseline
assessment.
Main Independent Variables
Heavy Alcohol Use
The TLFB survey asked subjects to recall the amount of
alcohol consumed on each of the 30 days prior to entering
treatment. From these data on their average weekly intake,
alcohol status was classiﬁed into the following two cate-
gories: heavy (>seven drinks/week for women and >14/
week for men) and not heavy (alcohol use less than heavy
thresholds). We chose these categories to be consistent
with National Institute on Alcohol Abuse and Alcoholism
recommendations for heavy drinking. There are no estab-
lished heavy drinking limits in Russia.
Cannabis Use
The TLFB survey in all cohorts asked subjects to recall
cannabis use on each of the 30 days prior to entering
treatment. We categorized subjects with any cannabis use
in the 30 days prior as a cannabis user and those with no
cannabis use as a cannabis non-user.
Outcomes
Measures of HIV Drug-Risk Behavior
The primary outcome of the study was the drug RAB score,
modeled as a continuous variable. The drug RAB score
ranges from 0to 25. Injectingdrugs within the last6 months
scored 1 point. Additional points were scored for needle
sharing, equipment sharing, injecting in group settings, and
mixing and sharing drugs. Among a prospectively followed
group of IDUs in the United States, the drug RAB was able
to discriminate those who seroconverted from those who
remained seronegative for HIV infection (Metzger et al.,
2001). A secondary outcome was risky drug use in the past
6 months. We deﬁned risky drug use as having a drug RAB
score greater than 1, which indicates some needle, equip-
ment, or drug sharing in the last 6 months.
Data Analysis
We performed descriptive analyses (e.g. means, medians,
standard deviations, proportions) for the following vari-
ables: age, sex, employment status, HIV status (available
for PREVENT study only), stimulant use, cannabis use,
heavy alcohol use, mean drug RAB score, and risky drug
use. Subjects in the two naltrexone trials were grouped into
the Naltrexone cohort (n = 332) and compared to the
PREVENT cohort (n = 72) using two-sample t-tests or v
2
tests. We assessed whether heavy alcohol use and cannabis
use were associated with drug RAB score using multiple
linear regression models, adjusting for age, sex, employ-
ment status, stimulant use and study cohort as covariates.
Logistic regression models were used to analyze the sec-
ondary dichotomous outcome, risky drug use. To assess
whether the effect of heavy alcohol use and cannabis use
was similar for both cohorts, regression models were also
ﬁt separately for each cohort. For the PREVENT cohort,
we performed an additional model that included a covariate
for HIV status. All analyses were conducted using two-
sided tests and a signiﬁcance level of 0.05.
Results
Characteristics of the combined and individual cohorts are
presented in Table 1. The combined cohort included 27%
women, 28% employed, 13% stimulant users, 10% drink-
ing at heavy levels, and 91% with a drug RAB score
greater than 1. The Naltrexone and PREVENT cohorts
were similar overall, but the PREVENT cohort was older
(27 years vs. 23; t(402) = 5.81; P < 0.01); had more can-
nabis users (33% vs. 22%; v
2 (1, n = 404) = 4.06;
P < 0.05); and had a higher mean drug RAB score (12.6 vs.
8.0; t(402) = 6.86; P < 0.01). HIV infection status was
only known for the PREVENT cohort, in which 35% were
HIV-infected. The cohorts were similar with regards to
gender, employment, stimulant use and heavy alcohol use.
When stratiﬁed by heavy alcohol use, characteristics were
similar for heavy and non-heavy alcohol users. When
stratiﬁed by cannabis use, cannabis and non-cannabis users
were similar on all characteristics except cannabis users
were more likely to use stimulants (22% vs. 10%; v
2 (1,
n = 404) = 9.96; P < 0.01).
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123Table 2 displays the bivariate analyses of cannabis use
and heavy alcohol use with drug RAB score and risky drug
use. In unadjusted analyses, cannabis users had a higher
mean drug RAB score compared to non-users (10.2 vs. 8.5;
t(402) = 2.74; P < 0.01), however there was no difference
in the proportion of risky drug use (93% vs. 91%; v
2 (1,
n = 404) = 0.71; ns). We did not ﬁnd a signiﬁcant differ-
ence in drug RAB score between heavy and non-heavy
drinkers (9.6 vs. 8.8; t(402) = 0.89; ns), however, heavy
drinkers were more likely to be risky IDUs (100% versus
90%; Fisher’s exact test; P < 0.05), as deﬁned above in
‘‘Outcomes’’.
In multiple regression analyses, the mean drug RAB
score remained higher for cannabis users compared to non-
cannabis users (adjusted mean difference 1.09 points;
t(402) = 1.82; ns; Table 3), however the magnitude of the
association was attenuated and no longer statistically sig-
niﬁcant. Because cannabis use has been described as a
gateway drug, and therefore may precede stimulant use in
the causal pathway, we performed an adjusted analysis that
did not include stimulant use which showed cannabis users
had a mean drug RAB score 1.25 points higher than non-
cannabis users (t(402) = 2.10; P < 0.05). No statistically
signiﬁcant association between heavy alcohol use and the
continuous drug RAB score was detected in both the model
adjusted for stimulant use (adjusted mean difference in
drug RAB score 0.59 for heavy versus non-heavy alcohol
use; t(402) = 0.71; ns) and the model that was not (adjusted
mean difference 0.63; t(402) = 0.76; ns). Signiﬁcant asso-
ciations with lower drug RAB scores among covariates
included older age, current employment, and participation
in the Naltrexone cohort.
In secondary multiple linear regression analyses strati-
ﬁed by study cohort, associations between cannabis use and
higher drug RAB scores were observed for both cohorts;
however, the associations were not statistically signiﬁcant.
In both study cohorts, older age was signiﬁcantly associ-
ated with lower drug RAB scores. Current employment
was associated with lower RAB scores, though statistically
signiﬁcant for the PREVENT cohort, but not the Naltrex-
one cohort. In the PREVENT cohort analysis that included
HIV status, subjects with HIV infection had higher drug
RAB scores than those who were not HIV-infected (the
mean drug RAB score was 4.6 points higher for HIV
positive versus HIV negative subjects, t(70) = 3.26;
P < 0.01).
Table 1 Characteristics of IDUs in St. Petersburg overall and stratiﬁed by study cohort
Total n = 404 PREVENT n = 72 Naltrexone n = 332 Test statistic
a
Age, mean (SD) 23.9 (4.5) 26.6 (4.9) 23.4 (4.2) 5.81**
Male, no. (%) 294 (73) 49 (68) 245 (74) 0.98
Employed, no. (%) 111 (28) 18 (25) 93 (28) 0.27
HIV status, no. (%)
Positive 25 (6) 25 (35) 0 NA
Negative 47 (12) 47 (65) 0
Unknown 332 (82) 0 332 (100)
Stimulant use, no. (%) 51 (13) 12 (17) 39 (12) 1.28
Cannabis use, no. (%) 97 (24) 24 (33) 73 (22) 4.06*
Heavy alcohol use no. (%) 40 (10) 7 (10) 33 (10) 0.0051
Risky IDU, no. (%) 368 (91) 67 (93) 301 (91) 0.42
Mean drug RAB score (SD) 8.9 (5.4) 12.6 (6.3) 8.0 (4.9) 6.86**
* P < 0.05, ** P < 0.01
a t-tests (degrees of freedom = 402) and v
2 tests (degrees of freedom = 1)
Table 2 Bivariate comparisons of heavy alcohol use, cannabis use with drug risk behaviors
Mean drug RAB score (SD) T-test statistic (df = 400) Risky IDU, no. (%) v
2 statistic (df = 1)
Heavy alcohol use 9.6 (5.3) –0.89 40 (100) *
,a
No heavy alcohol use 8.8 (5.4) 326 (90)
Cannabis use 10.2 (5.5) 2.74** 90 (93) 0.47
No cannabis use 8.5 (5.3) 276 (91)
* P < 0.05, ** P < 0.01
a Calculated using Fisher’s exact test
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showed no signiﬁcant association between cannabis use
and the secondary outcome risky drug use (unadjusted
Odds Ratio 1.35; 95% conﬁdence interval 0.57–3.19; v
2 (1,
n = 402) = 0.47; ns; adjusted Odds Ratio 1.30; 95% con-
ﬁdence interval 0.53–3.17; v
2 (1, n = 402) = 0.32; ns). In
logistic regression models including heavy alcohol use as
an independent variable, odds ratios were not estimable as
all heavy drinkers were risky drug users.
Discussion
Reducing drug-related HIV transmission in Russia will
require wide adoption by the existing public health systems
of effective prevention and treatment efforts, such as nee-
dle exchange programs, increased access to naltrexone and
availability of methadone or buprenorphine replacement
programs. Understanding the relationship between sub-
stance use (e.g., alcohol, cannabis, and stimulants) and
injection drug use practices should inform the implemen-
tation of these programs. We hypothesized that among
heroin dependent patients entering treatment in Russia,
both heavy alcohol use and cannabis use would be inde-
pendently associated with risky drug use behaviors. In
unadjusted analysis, we found a statistically signiﬁcant
increase in drug RAB score among cannabis users. But in a
multiple regression analysis this association was attenuated
and not statistically signiﬁcant after adjustment for stimu-
lant use. We did not detect a signiﬁcant association
between heavy alcohol use and drug RAB score, yet we
found that all heavy alcohol users had some needle,
equipment, or drug sharing in the last 6 months.
How could cannabis use increase HIV drug risk
behaviors? Research focused on the relationship of can-
nabis use and HIV drug risk behaviors is limited. Cannabis
use is associated with the use of other drugs and frequently
precedes the use of injectable drugs, such as heroin and
cocaine (Fergusson, Boden, & Horwood, 2006; Golub &
Johnson, 1994; Lynskey et al., 2003). A French cohort
study of HIV-infected IDUs found that cessation of injec-
tion drug use was associated with decreased cannabis use
(Bouhnik et al., 2004). No studies have directly assessed
the hypothesis that cannabis use is associated with risky
drug behaviors, either directly via immediate disinhibitory
effects or as a marker of risky behavior.
Kozlov et al. reported increased incidence of HIV
seroconversion among IDUs in St. Petersburg who use
stimulants (Kozlov et al., 2006). Incidence was further
increased with greater weekly injection frequency, how-
ever this study did not examine the impact of other drugs,
such as alcohol or cannabis. It is possible that an associa-
tion between heavy alcohol use, cannabis use and increased
risk behaviors, as well as stimulant use and increased HIV
seroconversion are examples of polysubstance use driving
increased risk taking. In our adjusted model that did not
include stimulant use, we found a signiﬁcant association
between cannabis use and increased drug RAB score, yet
this association was attenuated and not signiﬁcant in the
model that included stimulant use. This attenuation may
occur because cannabis use is a marker of one or more
factors, such as stimulant use, which increases risk taking.
Cannabis may be used concomitantly to attenuate the
dysphoric results of stimulant use, or cannabis use may
precede stimulant use in a causal pathway where cannabis
use leads to stimulant use and then to increased risk taking.
The impact of cannabis use on HIV sex risk behaviors
has been described (Brodbeck, Matter, &, Moggi, 2006;
Simbayi et al., 2004; Somlai et al., 2002; Woody et al.,
1999) but results have not always been inconsistent.
Woody et al. (1999) found that cannabis use was not
associated with increased sex risk among gay men, while
Table 3 Multiple linear regression models assessing the impact of heavy alcohol use and cannabis use on drug RAB score among IDUs in St.
Petersburg (n = 404)
Adjusted for stimulant use Not adjusted for stimulant use
Mean change
in drug RAB
Standard error T-value Mean change
in drug RAB
Standard error T-value
Heavy alcohol use +0.59 0.84 0.71 +0.63 0.84 0.76
Cannabis use +1.09 0.60 1.82 +1.25 0.59 2.10*
Age
a –0.23 0.059 –4.07** –0.24 0.059 –4.15**
Female vs. Male –0.30 0.57 –0.52 –0.23 0.57 –0.41
Employed –1.47 0.56 –2.63** –1.53 0.56 –2.74**
Naltrexone vs. PREVENT cohort –5.13 0.68 –7.52** –5.19 0.68 –7.60**
Stimulant use +1.28 0.77 1.67 X X X
* P < 0.05, ** P < 0.01
a Adjusted mean corresponding to a 1 year increase in age
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123Brodbeck et al. (2006) found in a random sample of Swiss
heterosexuals that cannabis use was associated with
increased HIV sex risk behaviors, though not speciﬁcally at
the time they were using cannabis. This is evidence that
cannabis use is a marker of a riskier personality, or
increases risk via chronic effects rather than directly
increasing sex risk during the time it is used. In addition,
chronic use may affect general risk taking by lowering
motivation to protect oneself. If the effect of cannabis use
is primarily an increase in general risk taking rather than
acute situational risk taking, its use likely increases both
HIV drug and sexual behaviors through a similar mecha-
nism. HIV risk behavior research that addresses the impact
of acute and chronic cannabis use on measures of moti-
vation might further clarify the mechanism by which can-
nabis may increase risk behaviors.
Results of studies on alcohol’s relationship to HIV risk
among IDUs in the United States are mixed. Alcohol use
among needle exchange participants in Providence, RI has
been associated with increased injection and sexual risk
(Stein et al., 2000). Using 30-day TLFB for both risky
injection drug use and alcohol use, an association has been
shown between daily alcohol use and daily risky injection
(Stein, Charuvastra, Anderson, Sobota, & Friedmanna,
2002). Among Puerto Rican IDUs not in treatment, alcohol
intoxication has been associated with sharing needles and
cotton ﬁlters (Matos et al., 2004). However, among
detoxiﬁcation inpatients in Boston, alcohol consumption
was associated with increased sexual risk, but not injection
risk (Rees, Saitz, Horton, & Samet, 2001). Studies in
Russia have shown that among HIV-infected inpatients,
alcohol abuse or dependence has a signiﬁcant association
with sexual risk and a non-signiﬁcant association with
injection risk (Krupitsky et al., 2005). Among young
injection drug users in St. Petersburg, Somlai et al. (2002)
reported a 40% rate of needle sharing in the previous
90 days and a 74% rate of alcohol use in the previous
30 days, but this study did not look speciﬁcally at the
association between alcohol and risky injection.
Alcohol and drug use disorders often co-occur in US
populations (Belenko, 1979; Kessler et al., 1997), yet these
Russian IDUs had a low percentage (10%) of heavy
drinking. With the high overall prevalence of alcohol use in
Russia, we expected to ﬁnd higher rates of alcohol use
among heroin users. The low proportion of heavy drinkers
in these samples limited our ability to detect a signiﬁcant
association with risky drug behaviors. In unadjusted anal-
yses, we found an association between heavy drinking and
the secondary dichotomous outcome, risky drug use, but
we were unable to estimate odds ratios from logistic
regression models as all heavy drinkers also had risky drug
behaviors. We did not ﬁnd an association between heavy
drinking and the continuous drug RAB score, however the
measure of heavy drinking we used was developed in the
United States and may not be the optimal measure in
Russia. Because Russians consume more alcohol than
Americans, it is conceivable that the optimal Russian
measure may be a higher threshold, which in this study
would have the impact of categorizing even fewer heavy
drinkers. Despite the absence of a statistically signiﬁcant
association, we caution that alcohol may still represent an
important predictor of HIV drug risk behaviors. As risky
drug practices in Russia improve with more prevention
education and optimal measures of heavy alcohol use in
Russia are developed, a relationship between alcohol use
and risky injection drug use may be revealed, as the heavy
drinkers may be slow adopters of safer injection behaviors.
Alternatively, the impact of heavy alcohol use may be
limited to sexual risk behaviors.
The association of HIV infection with increased drug
RAB scores observed in the PREVENT cohort is consistent
with the rapid spread of HIV among IDUs in Russia.
Furthermore, the mean drug RAB scores in both cohorts
were higher than those seen among drug using Russian
(Krupitsky et al., 2005) and American (Rees et al., 2001;
Stein et al., 2000) cohorts and may well reﬂect increased
risky drug behavior in Russia. The higher means among the
PREVENT cohort relative to the Naltrexone cohort may be
explained by the data collection methods. In PREVENT,
drug risk behaviors were assessed with the use of the
ACASI system which likely reduces social desirability bias
and increases truth telling, whereas the Naltrexone cohort
was assessed with one-on-one interviews, similar to the
other studies that have used the RAB instrument.
There are several limitations to our study. First, our
analysis was potentially underpowered to detect effects of
the observed magnitude for cannabis and heavy alcohol
use. Post-hoc calculations indicate that our study would
have approximately 80% power to detect a minimum dif-
ference in drug RAB score of 2.5 and 1.8 for heavy
drinking and cannabis use, respectively. Thus, it is likely
that the study was not sufﬁciently powered to detect the
observed magnitudes of association. Second, this is a cross-
sectional analysis of baseline data, which limits our ability
to establish causality, as well as the order of preceding
causal elements. Third, this study combines results from
three different cohorts that enrolled subjects at different
times. However, the subjects were recruited and enrolled
by similar study staff from similar settings and provided
similar data. Fourth, while we did adjust for age, gender,
and employment, future research should examine the im-
pact of other psychosocial factors, such as mental illness on
drug-related HIV risk behavior. Fifth, as all subjects came
from the St. Petersburg area and were entering treatment,
they may not adequately represent all Russian IDUs. IDUs
entering treatment are likely to be more motivated to re-
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nabis use as well. Therefore it is possible that they may
have fewer drug-related risk behaviors before entering
treatment. If this were the case, then this would decrease
the likelihood we would ﬁnd an association. Sixth,
although we had cannabis use and heavy alcohol use data
via the 30-day TLFB method, our risk behavior data was
limited to the drug RAB score, which encompasses the
prior 6 months. Collecting drug and alcohol use informa-
tion as well as drug behavior information on a day-by-day
basis would allow for examination of the daily relationship
between substance use and risky behaviors.
Among 404 Russian IDUs entering treatment for heroin
dependence, all heavy alcohol users had risky drug
behaviors, but we did not ﬁnd signiﬁcant evidence of an
association between heavy alcohol use and the HIV drug
RAB score in unadjusted or adjusted analyses. We did ﬁnd
a signiﬁcant association between cannabis use and drug
RAB score after adjustment for age, sex, and employment
status. Yet when adjusted for stimulant use, the association
between cannabis use and HIV drug risk behaviors was
attenuated and not statistically signiﬁcant. Because of the
central role of IDUs in the rapidly progressing Russian HIV
epidemic, it is important to understand how the use of
multiple substances, including cannabis and alcohol,
impacts risky drug behaviors among IDUs.
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